Analyst Price Targets — HAE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 6, 2026 2:45 pm | — | Robert W. Baird | $81.00 | $61.40 | TheFly | Haemonetics price target lowered to $81 from $99 at Baird |
| February 6, 2026 12:37 pm | — | Barrington | $94.00 | $65.02 | TheFly | Haemonetics price target raised to $94 from $93 at Barrington |
| February 6, 2026 12:36 pm | — | Mizuho Securities | $80.00 | $65.02 | TheFly | Haemonetics price target lowered to $80 from $90 at Mizuho |
| January 12, 2026 12:37 pm | — | Barrington | $93.00 | $82.03 | TheFly | Haemonetics price target raised to $93 from $90 at Barrington |
| December 17, 2025 11:57 am | — | Mizuho Securities | $90.00 | $81.11 | TheFly | Haemonetics price target raised to $90 from $75 at Mizuho |
| December 15, 2025 2:16 pm | — | Robert W. Baird | $99.00 | $80.33 | TheFly | Haemonetics price target raised to $99 from $87 at Baird |
| November 14, 2025 9:22 am | Andrew Cooper | Raymond James | $90.00 | $73.91 | StreetInsider | Haemonetics (HAE) PT Raised to $90 at Raymond James |
| November 6, 2025 6:30 pm | — | BTIG | $88.00 | $66.20 | TheFly | Haemonetics price target raised to $88 from $85 at BTIG |
| August 7, 2025 4:49 pm | Mike Matson | Needham | $68.00 | $55.64 | TheFly | Haemonetics price target lowered to $68 from $84 at Needham |
| November 8, 2024 8:49 am | Andrew Cooper | Raymond James | $120.00 | $74.83 | StreetInsider | Raymond James Upgrades Haemonetics (HAE) to Strong Buy |
Latest News for HAE
The Touchstone Small Cap Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell 2000® Index, for the quarter ended December 31, 2025. The best performing stocks based on relative performance vs. the benchmark during the quarter included White Mountains Insurance Group, Revolve Group Inc. and Haemonetics Corp. The more challenged positions based on relative performance during the quarter included…
BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the NexSys PCS ® Plasma Collection System with Persona ® PLUS technology. Persona PLUS represents the next generation of Haemonetics' proprietary…
BOSTON, Feb. 20, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026 at 10:25 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link:…
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the newly published International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema recommends EKTERLY® (sebetralstat) as a first-line therapy for the acute treatment of hereditary angioedema (HAE) attacks in adolescents aged 12 years and older.1 Based…
The London Company Small Cap portfolio increased 2.7% (2.5% net) during the quarter vs. a 2.2% increase in the Russell 2000 Index. Contributors to relative performance were White Mountains Insurance Group Ltd, Revolve Group Inc. and Haemonetics Corporation. Detractors from relative performance were NewMarket Corporation, Certara, Inc. and Gates Industrial Corporation plc.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HAE.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.